Substernal lead removal: experience from the EV ICD pivotal study

• Published in: Europace (London, England) Vol. 26; no. Supplement_1
• Main Authors: Amin, A, Crozier, I, Murgatroyd, F, Boersma, L V A, Manlucu, J, Knight, B P, Leclercq, C, Birgersdotter-Green, U M, Chan, J Y S, Roukoz, H, Biffi, M, Sagi, V, Wiggenhorn, C, Friedman, P
• Format: Journal Article
• Language: English
• Published: 24-05-2024
• ISSN: 1099-5129; 1532-2092
• DOI: 10.1093/europace/euae102.445

Abstract
Background
The extravascular implantable cardioverter defibrillator (EV ICD) has recently emerged as a new option for guideline indicated ICD patients. Previous study results from the EV ICD Pilot and Pivotal studies have demonstrated that the device can provide safe and effective therapy through chronic follow up. However, less has been reported regarding EV ICD lead removal.
Purpose
To report on the experience of lead removal in the EV ICD Pivotal Study.
Methods
The EV ICD Pivotal study was an international, prospective, single-arm, premarket clinical study. Patients with a class I or IIa indication for a single-chamber ICD per ESC or ACC/AHA/HRS guidelines were enrolled. Lead removal summary data was reported.
Results
Of 316 patients with an implant attempt, (74.7% male, age 53.8±13.1 years, 82% primary prevention, LVEF of 38.9%±15.4%, and NYHA Class I [23.7%] or II/III [65.5%]) 299 were fully implanted; 17 (5.7%) of which had a lead removal procedure (14–752 days post-implant, at 13 sites) with 3 of them having been implanted for more than 1 year. Reasons for lead removal were lead dislodgement (n=7), infection (n=5), high impedance alert due to lead fracture (n=2), pacing indication (n=1), cardiac transplant (n=1), or scheduled sternotomy (n=1). New EV ICD leads were placed in 7/17 (41.2%) patients. No serious adverse events were adjudicated as related to the explant procedures. There was a single observation of incision site haemorrhage, that was resolved with wound care. Additional details on lead removal will be included at the time of presentation.
Conclusions
The EV ICD lead was successfully removed 14-752 days post implant. Nine patients were re-implanted with either extravascular or transvenous systems. Longer term extraction data collection is ongoing through the EV ICD Pivotal study and through the EV ICD post-approval study and will continue to provide additional insights.Lead removed 24 months post-implant.